The short version of peptide agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-31. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
==== Member of the Order of the British Empire (MBE) ==== Military Division Royal Navy Chief Petty Officer (Operations) (Radar) Alan James Baker, D077088R. Chief Petty Officer Air Engineering Artificer (L) Stephen Michael Baker, D109087R. Lieutenant Commander Harry Colin Cook. Lieutenant Commander Alan Robert Cronin. Lieutenant Commander Reginald Keith Elsworth. Lieutenant Commander David Michael Foster. Sergeant Steven Paul Goodwin, Royal Marines, P040469W. Lieutenant Commander (SCC) Denise Lilian Gravestock, Royal Navy Reserve. Lieutenant Commander (Acting Commander) Hubert Frederick Hatton. Warrant Officer Peter Robert Jones. Lieutenant Commander Simon John Nicholson Kings. Warrant Officer Michael Stephen Lacey. Warrant Officer Class 1 Peter Lawton, Royal Marines. Lieutenant Commander (now Commander) Christopher Charles Leggett. Lieutenant Commander Anthony Joseph Mawson. Warrant Officer Harold Milne. Lieutenant Commander (now Acting Commander) Geoffrey Charles Pell. Chief Petty Officer (Diver) John Robert Smith, D053657P. Colour Sergeant Alan Keith Turner, Royal Marines, P032549Y. Warrant Officer Nigel Frank Wallace. Lieutenant (now Lieutenant Commander) Geoffrey Ian Woodford. Warrant Officer Simon Yui Kwok Choi. Army The Reverend John Stephen Alker (513792), Chaplain to the Forces (3rd Class), Royal Army Chaplains' Department. Major James Victor Glen Bain (520977), The Argyll and Sutherland Highlanders. 24821742 Corporal Christopher David Ernest Bessey, The Royal Logistic Corps. Lieutenant Russell John Bishop (546098), The Parachute Regiment.
Ingesting a compound by smoking is one of the most rapid and efficient methods of introducing it into the bloodstream, second only to injection, which allows for the rapid feedback which supports the smokers' ability to titrate their dosage. On average it takes about ten seconds for the substance to reach the brain. As a result of the efficiency of this delivery system, many smokers feel as though they are unable to cease. Those who achieve one year of continuous abstinence are highly likely to remain so, with the vast majority of relapses occurring within the first eight days after attempting cessation. There exists a possibility of depression in some who attempt cessation, as with other psychoactive substances. Depression is also common in teenage smokers; teens who smoke are four times as likely to develop depressive symptoms as their non-smoking peers. Although nicotine does play a role in acute episodes of some diseases (including stroke, impotence, and heart disease) by its stimulation of adrenaline release, which raises blood pressure, heart and respiration rate, and free fatty acids, the most serious longer term effects are more the result of the products of the smoldering combustion process. This has led to the development of various nicotine delivery systems, such as the nicotine patch or nicotine gum, that can satisfy the addictive craving by delivering nicotine without the harmful combustion by-products. This can help the heavily dependent smoker to quit gradually while discontinuing further damage to health.
Ketone bodies can be used as fuels, yielding 22 ATP and 2 GTP molecules per acetoacetate molecule when oxidized in the mitochondria. Ketone bodies are transported from the liver to other tissues, where acetoacetate and beta-hydroxybutyrate can be reconverted to acetyl-CoA to produce reducing equivalents (NADH and FADH2), via the citric acid cycle. Ketone bodies cannot be used as fuel by the liver, because the liver lacks the enzyme β-ketoacyl-CoA transferase, also called thiolase. Acetoacetate in low concentrations is taken up by the liver and undergoes detoxification through the methylglyoxal pathway which ends with lactate. Acetoacetate in high concentrations is absorbed by cells other than those in the liver and enters a different pathway via 1,2-propanediol. Though the pathway follows a different series of steps requiring ATP, 1,2-propanediol can be turned into pyruvate.
was the conserved vis viva. It was later shown that both quantities are conserved simultaneously given the proper conditions, such as in an elastic collision. In 1687, Isaac Newton published his Principia, which set out his laws of motion. It was organized around the concept of force and momentum. However, the researchers were quick to recognize that the principles set out in the book, while fine for point masses, were not sufficient to tackle the motions of rigid and fluid bodies. Some other principles were also required. By the 1690s, Leibniz was arguing that conservation of vis viva and conservation of momentum undermined the then-popular philosophical doctrine of interactionist dualism. (During the 19th century, when conservation of energy was better understood, Leibniz's basic argument would gain widespread acceptance. Some modern scholars continue to champion specifically conservation-based attacks on dualism, while others subsume the argument into a more general argument about causal closure.)
Sources: en.wikipedia.org
Labetalol is a medication used to treat high blood pressure and in long term management of angina. This includes essential hypertension, hypertensive emergencies, and hypertension of pregnancy. In essential hypertension it is generally less preferred than a number of other blood pressure medications. It can be given by mouth or by injection into a vein. Common side effects include low blood pressure with standing, dizziness, feeling tired, and nausea. Serious side effects may include low blood pressure, liver problems, heart failure, and bronchospasm. Use appears safe in the latter part of pregnancy and it is not expected to cause problems during breastfeeding. It works by blocking the activation of β- and α-adrenergic receptors. Labetalol was patented in 1966 and came into medical use in 1977. It is available as a generic medication. In 2023, it was the 232nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.
=== Hezbollah and Hamas === At a 22 July 2006 demonstration (and later in a Socialist Worker op-ed), Galloway stated that "Hizbollah is not and has never been a terrorist organisation. It is the legitimate national resistance movement of Lebanon". He further said: "The invasion of Lebanon by Israel, for that's what it is, is a monstrous injustice. I side with the resistance to that injustice. Hizbollah is leading that resistance. ... I glorify the Hizbollah national resistance movement, and I glorify the leader of Hizbollah, Sayyed Hassan Nasrallah". In 2009, Galloway received a Palestinian passport from Hamas leader Ismail Haniyeh. Hamas is designated as a terrorist organisation by Israel, the European Union, the United Kingdom, and the United States. He was denied entry into Canada on national security grounds, with Alykhan Velshi, then a spokesman for Jason Kenney, Canada's immigration minister, commenting: "We're going to uphold the law, not give special treatment to this infandous street-corner Cromwell who actually brags about giving 'financial support' to Hamas, a terrorist organisation banned in Canada." After a 2010 investigation into the actions of Velshi and other staffers in Kenney's office and into decisions made by bureaucrats prior to Galloway's visit, Justice Richard Mosley ruled that the government's decision to ban Galloway was politically motivated. A week after Mosley's ruling, Galloway travelled to Canada.
=== Fossil record === The earliest widely accepted animal fossils are rather modern-looking cnidarians, possibly from around 580 million years ago, although fossils from the Doushantuo Formation can only be dated approximately. The identification of some of these as embryos of animals has been contested, but other fossils from these rocks strongly resemble tubes and other mineralized structures made by corals. Their presence implies that the cnidarian and bilaterian lineages had already diverged. Although the Ediacaran fossil Charnia used to be classified as a jellyfish or sea pen, more recent study of growth patterns in Charnia and modern cnidarians has cast doubt on this hypothesis, leaving the Canadian polyp Haootia and the British Auroralumina as the only recognized cnidarian body fossils from the Ediacaran. Auroralumina is the earliest known animal predator. Few fossils of cnidarians without mineralized skeletons are known from more recent rocks, except in Lagerstätten that preserved soft-bodied animals. A few mineralized fossils that resemble corals have been found in rocks from the Cambrian period, and corals diversified in the Early Ordovician. These corals, which were wiped out in the Permian–Triassic extinction event about 252 million years ago, did not dominate reef construction since sponges and algae also played a major part. During the Mesozoic era, rudist bivalves were the main reef-builders, but they were wiped out in the Cretaceous–Paleogene extinction event 66 million years ago, and since then the main reef-builders have been scleractinian corals.
Alongside the general election, voters were asked to participate in a referendum regarding a proposed rewrite of the country's 2017 Constitution. On election night, unofficial results reported by Al Jazeera indicated that more than 57 per cent of voters had supported the drafting of a new constitution. People's Party leader Natthaphong Ruengpanyawut acknowledged that the referendum appeared to have been approved and stated his party would respect the parliamentary process. The proposal was carried. According to the Election Commission, 21,621,638 voters (60.16 per cent) approved the drafting of a new constitution, 11,241,653 (31.28 per cent) rejected it and 3,074,330 (8.55 per cent) expressed no opinion, from 35,937,621 valid ballots. A further 932,583 ballots were rejected as invalid. Turnout in the referendum was 36,870,266, or 69.65 per cent, about 937,000 fewer ballots than were cast in the general election held the same day. Support was broadly spread, with 288 of the 400 constituencies recording a 'yes' vote above 70 per cent and only 38 recording a 'no' vote above 50 per cent, two of them in Buriram and the remaining 36 in the upper south.
==== Coal ==== Coal contains a small amount of radioactive uranium, barium, thorium, and potassium, but, in the case of pure coal, this is significantly less than the average concentration of those elements in the Earth's crust. The surrounding strata, if shale or mudstone, often contain slightly more than average and this may also be reflected in the ash content of 'dirty' coals. The more active ash minerals become concentrated in the fly ash precisely because they do not burn well. The radioactivity of fly ash is about the same as black shale and is less than phosphate rocks, but is more of a concern because a small amount of the fly ash ends up in the atmosphere where it can be inhaled. According to U.S. National Council on Radiation Protection and Measurements (NCRP) reports, population exposure from 1000-MWe power plants amounts to 490 person-rem/year for coal power plants, 100 times as great as nuclear power plants (4.8 person-rem/year). The exposure from the complete nuclear fuel cycle from mining to waste disposal is 136 person-rem/year; the corresponding value for coal use from mining to waste disposal is "probably unknown".
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.